Collective Family Office LLC Has $207,000 Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Collective Family Office LLC lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 41.3% in the 4th quarter, Holdings Channel reports. The firm owned 2,407 shares of the biopharmaceutical company’s stock after selling 1,696 shares during the quarter. Collective Family Office LLC’s holdings in Gilead Sciences were worth $207,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of GILD. Premier Fund Managers Ltd raised its holdings in Gilead Sciences by 62.0% in the 3rd quarter. Premier Fund Managers Ltd now owns 8,746 shares of the biopharmaceutical company’s stock worth $552,000 after acquiring an additional 3,346 shares during the period. Avantax Planning Partners Inc. bought a new position in Gilead Sciences in the 3rd quarter worth $229,000. Brookstone Capital Management raised its holdings in Gilead Sciences by 5.7% in the 3rd quarter. Brookstone Capital Management now owns 169,160 shares of the biopharmaceutical company’s stock worth $11,061,000 after acquiring an additional 9,145 shares during the period. Gladstone Institutional Advisory LLC raised its holdings in Gilead Sciences by 8.5% in the 3rd quarter. Gladstone Institutional Advisory LLC now owns 15,099 shares of the biopharmaceutical company’s stock worth $931,000 after acquiring an additional 1,180 shares during the period. Finally, Moody National Bank Trust Division raised its holdings in Gilead Sciences by 27.7% in the 3rd quarter. Moody National Bank Trust Division now owns 29,923 shares of the biopharmaceutical company’s stock worth $1,846,000 after acquiring an additional 6,492 shares during the period. Institutional investors and hedge funds own 78.72% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 6,126 shares of the business’s stock in a transaction dated Monday, March 13th. The shares were sold at an average price of $78.99, for a total value of $483,892.74. Following the transaction, the insider now directly owns 70,130 shares in the company, valued at $5,539,568.70. The transaction was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Oppenheimer lifted their target price on shares of Gilead Sciences from $95.00 to $105.00 in a report on Thursday, December 1st. Wells Fargo & Company boosted their price objective on shares of Gilead Sciences from $75.00 to $90.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 3rd. Bank of America restated a “neutral” rating and set a $85.00 price objective on shares of Gilead Sciences in a report on Tuesday, December 13th. SVB Leerink boosted their price objective on shares of Gilead Sciences from $81.00 to $91.00 and gave the stock a “market perform” rating in a report on Friday, February 3rd. Finally, Barclays boosted their price objective on shares of Gilead Sciences from $76.00 to $84.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 18th. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $89.40.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $77.31 on Friday. The firm has a market cap of $96.41 billion, a PE ratio of 21.18, a price-to-earnings-growth ratio of 0.95 and a beta of 0.38. Gilead Sciences, Inc. has a 12 month low of $57.17 and a 12 month high of $89.74. The company has a quick ratio of 1.15, a current ratio of 1.29 and a debt-to-equity ratio of 1.14. The company’s 50-day moving average price is $83.20 and its two-hundred day moving average price is $78.51.

Gilead Sciences (NASDAQ:GILD – Get Rating) last released its quarterly earnings results on Thursday, February 2nd. The biopharmaceutical company reported $1.67 EPS for the quarter, beating analysts’ consensus estimates of $1.50 by $0.17. The firm had revenue of $7.39 billion for the quarter, compared to analyst estimates of $6.63 billion. Gilead Sciences had a net margin of 16.83% and a return on equity of 44.46%. The company’s revenue for the quarter was up 2.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.69 earnings per share. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 6.86 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 30th. Shareholders of record on Wednesday, March 15th will be given a $0.75 dividend. The ex-dividend date of this dividend is Tuesday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.73. This represents a $3.00 dividend on an annualized basis and a yield of 3.88%. Gilead Sciences’s payout ratio is 82.19%.

About Gilead Sciences

(Get Rating)

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.